Comparative Pharmacology
Head-to-head clinical analysis: CARMOL HC versus CORTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARMOL HC versus CORTAN.
CARMOL HC vs CORTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
None Documented
None Documented
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid